In silico identification of therapeutic compounds against microRNA targets in drug-resistant pancreatic ductal adenocarcinoma

References

• Adamska, A., Domenichini, A., & Falasca, M. (2017). Pancreatic ductal adenocarcinoma: Current and evolving therapies. International Journal of Molecular Sciences, 18(7), 1338. https://doi.org/10.3390/ijms18071338
   PubMed Web of Science ®Google Scholar
• Aier, I., Semwal, R., Dhara, A., Sen, N., & Varadwaj, P. K. (2019). An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma. PLoS One, 14(10), e0223554. https://doi.org/10.1371/journal.pone.0223554
   PubMed Web of Science ®Google Scholar
• Aier, I., Semwal, R., Sharma, A., & Varadwaj, P. K. (2019). A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer. Cancer Epidemiology, 58, 104–110. https://doi.org/10.1016/j.canep.2018.12.001
   PubMed Web of Science ®Google Scholar
• Amrutkar, M., & Gladhaug, I. P. (2017). Pancreatic cancer chemoresistance to gemcitabine. Cancers, 9(12), 157. https://doi.org/10.3390/cancers9110157
   Web of Science ®Google Scholar
• Arlt, A., Gehrz, A., Muerkoster, S., Vorndamm, J., Kruse, M. L., Folsch, U. R., & Schafer, H. (2003). Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 22(21), 3243–3251. https://doi.org/10.1038/sj.onc.1206390
   PubMed Web of Science ®Google Scholar
• Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., Harris, M. A., Hill, D. P., Issel-Tarver, L., Kasarskis, A., Lewis, S., Matese, J. C., Richardson, J. E., Ringwald, M., Rubin, G. M., & Sherlock, G. (2000). Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nature Genetics, 25(1), 25–29. https://doi.org/10.1038/75556
   PubMed Web of Science ®Google Scholar
• Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Dell'Aquila, M. L., Alder, H., Rassenti, L., Kipps, T. J., Bullrich, F., Negrini, M., & Croce, C. M. (2004). MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proceedings of the National Academy of Sciences of the United States of America, 101(32), 11755–11760. https://doi.org/10.1073/pnas.0404432101
   PubMed Web of Science ®Google Scholar
• Cheng, A. M., Byrom, M. W., Shelton, J., & Ford, L. P. (2005). Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Research, 33(4), 1290–1297. https://doi.org/10.1093/nar/gki200
   PubMed Web of Science ®Google Scholar
• Christensen, M., & Schratt, G. M. (2009). microRNA involvement in developmental and functional aspects of the nervous system and in neurological diseases. Neuroscience Letters, 466(2), 55–62. https://doi.org/10.1016/j.neulet.2009.04.043
   PubMed Web of Science ®Google Scholar
• Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J. L., Gourgou-Bourgade, S., de la Fouchardiere, C., Bennouna, J., Bachet, J. B., Khemissa-Akouz, F., Pere-Verge, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., … PRODIGE Intergroup. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 364(19), 1817–1825. https://doi.org/10.1056/NEJMoa1011923
   PubMed Web of Science ®Google Scholar
• Dong, Q. G., Sclabas, G. M., Fujioka, S., Schmidt, C., Peng, B., Wu, T., Tsao, M. S., Evans, D. B., Abbruzzese, J. L., McDonnell, T. J., & Chiao, P. J. (2002). The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene, 21(42), 6510–6519. https://doi.org/10.1038/sj.onc.1205848
   PubMed Web of Science ®Google Scholar
• Dubus, E., Ijjaali, I., Barberan, O., & Petitet, F. (2009). Drug repositioning using in silico compound profiling. Future Medicinal Chemistry, 1(9), 1723–1736. https://doi.org/10.4155/fmc.09.123
   PubMed Web of Science ®Google Scholar
• Firuzi, O., Che, P. P., El Hassouni, B., Buijs, M., Coppola, S., Lohr, M., Funel, N., Heuchel, R., Carnevale, I., Schmidt, T., Mantini, G., Avan, A., Saso, L., Peters, G. J., & Giovannetti, E. (2019). Role of c-MET inhibitors in overcoming drug resistance in spheroid models of primary human pancreatic cancer and stellate cells. Cancers, 11(5), 638. https://doi.org/10.3390/cancers11050638
   Web of Science ®Google Scholar
• Garajová, I., Le Large, T. Y., Frampton, A. E., Rolfo, C., Voortman, J., & Giovannetti, E. (2014). Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. BioMed Research International, 2014, 678401. https://doi.org/10.1155/2014/678401
   PubMed Web of Science ®Google Scholar
• Ge, S., & Jung, D. (2018). ShinyGO: A graphical enrichment tool for animals and plants. bioRxiv: 315150.
   Google Scholar
• Gnanamony, M., & Gondi, C. S. (2017). Chemoresistance in pancreatic cancer: Emerging concepts. Oncology Letters, 13(4), 2507–2513. https://doi.org/10.3892/ol.2017.5777
   PubMed Web of Science ®Google Scholar
• Heinemann, V. (2001). Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology, 60(1), 8–18. https://doi.org/10.1159/000055290
   PubMed Web of Science ®Google Scholar
• Heinemann, V. (2002). Gemcitabine-based combination treatment of pancreatic cancer. Seminars in Oncology, 29(6 Suppl 20), 9–35. https://doi.org/10.1053/sonc.2002.30749
   PubMed Web of Science ®Google Scholar
• NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. (2015). Pioglitazone in early Parkinson’s disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurology, 14, 795–803. https://doi.org/https://doi.org/10.1016/S1474-4422(15)00144-1
   PubMed Web of Science ®Google Scholar
• Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., & Friesner, R. A. (2004). A hierarchical approach to all-atom protein loop prediction. Proteins, 55(2), 351–367. https://doi.org/10.1002/prot.10613
   PubMed Web of Science ®Google Scholar
• Jiang, X., Hou, D., Wei, Z., Zheng, S., Zhang, Y., & Li, J. (2019). Extracellular and intracellular microRNAs in pancreatic cancer: From early diagnosis to reducing chemoresistance. ExRNA, 1(1) 17. https://doi.org/10.1186/s41544-019-0014-0
   Google Scholar
• Jen-Liang Su. (2016). The miRNA profiling in PANC-1, PANC-1 GEM 100 and PANC-1 GEM1500 cells, geo, V1 [dataset]. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79234
   Google Scholar
• Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., & Beger, H. G. (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. The Journal of Clinical Investigation, 90(4), 1352–1360. https://doi.org/10.1172/JCI116001
   PubMed Web of Science ®Google Scholar
• Korourian, A., Roudi, R., Shariftabrizi, A., & Madjd, Z. (2017). MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Experimental Biology and Medicine (Maywood, N.J.), 242(18), 1842–1847. https://doi.org/10.1177/1535370217728460
   PubMed Web of Science ®Google Scholar
• Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J. P., Subramanian, A., Ross, K. N., Reich, M., Hieronymus, H., Wei, G., Armstrong, S. A., Haggarty, S. J., Clemons, P. A., Wei, R., Carr, S. A., Lander, E. S., & Golub, T. R. (2006). The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science, 313(5795), 1929–1935. https://doi.org/10.1126/science.1132939
   PubMed Web of Science ®Google Scholar
• Li, C., Wu, J. J., Hynes, M., Dosch, J., Sarkar, B., Welling, T. H., Pasca di Magliano, M., & Simeone, D. M. (2011). c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology, 141(6), 2218–2227.e5. https://doi.org/10.1053/j.gastro.2011.08.009
   PubMed Web of Science ®Google Scholar
• Li, Y., & Sarkar, F. H. (2016). MicroRNA targeted therapeutic approach for pancreatic cancer. International Journal of Biological Sciences, 12(3), 326–337. https://doi.org/10.7150/ijbs.15017
   PubMed Web of Science ®Google Scholar
• Luo, W., Pant, G., Bhavnasi, Y. K., Blanchard, S. G., Jr., & Brouwer, C. (2017). Pathview Web: User friendly pathway visualization and data integration. Nucleic Acids Research, 45(W1), W501–W508. https://doi.org/10.1093/nar/gkx372
   PubMed Web of Science ®Google Scholar
• Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M., Haider, S. M., Morton, J. P., Marsico, G., Vo, T., Laughlin-Toth, S., Ahmed, A. A., Vita, G. D., Pazitna, I., Gunaratnam, M., Besser, R. J., Andrade, A. C. G., Diocou, S., Pike, J. A., Tannahill, D., Pedley, R. B., … Neidle, S. (2018). Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. Journal of Medicinal chemistry, 61(6), 2500–2517. https://doi.org/10.1021/acs.jmedchem.7b01781
   Google Scholar
• Meng, Q., Liang, C., Hua, J., Zhang, B., Liu, J., Zhang, Y., Wei, M., Yu, X., Xu, J., & Shi, S. (2020). A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: Functional validation and clinical significance. Theranostics, 10(9), 3967–3979. https://doi.org/10.7150/thno.40566
   PubMed Web of Science ®Google Scholar
• Muti, P., Donzelli, S., Sacconi, A., Hossain, A., Ganci, F., Frixa, T., Sieri, S., Krogh, V., Berrino, F., Biagioni, F., Strano, S., Beyene, J., Yarden, Y., & Blandino, G. (2018). MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: The hOrmone and Diet in the ETiology of breast cancer prospective study. Carcinogenesis, 39(2), 98–108. https://doi.org/10.1093/carcin/bgx126
   PubMed Web of Science ®Google Scholar
• Nakagawa, Y., Kuranaga, Y., Tahara, T., Yamashita, H., Shibata, T., Nagasaka, M., Funasaka, K., Ohmiya, N., & Akao, Y. (2019). Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Science, 110(8), 2540–2548. https://doi.org/10.1111/cas.14090
   PubMed Web of Science ®Google Scholar
• Pathan, M., Keerthikumar, S., Ang, C. S., Gangoda, L., Quek, C. Y., Williamson, N. A., Mouradov, D., Sieber, O. M., Simpson, R. J., Salim, A., Bacic, A., Hill, A. F., Stroud, D. A., Ryan, M. T., Agbinya, J. I., Mariadason, J. M., Burgess, A. W., & Mathivanan, S. (2015). FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics, 15(15), 2597–2601. https://doi.org/10.1002/pmic.201400515
   PubMed Web of Science ®Google Scholar
• Polvani, S., Tarocchi, M., Tempesti, S., & Galli, A. (2014). Nuclear receptors and pathogenesis of pancreatic cancer. World Journal of Gastroenterology, 20(34), 12062–12081. https://doi.org/10.3748/wjg.v20.i34.12062
   PubMed Web of Science ®Google Scholar
• Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., Norris, A., Sanseau, P., Cavalla, D., & Pirmohamed, M. (2019). Drug repurposing: Progress, challenges and recommendations. Nature Reviews. Drug Discovery, 18(1), 41–58. https://doi.org/10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Rawla, P., Sunkara, T., & Gaduputi, V. (2019). Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World Journal of Oncology, 10(1), 10–27. https://doi.org/10.14740/wjon1166
   PubMedGoogle Scholar
• Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010). edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics (Oxford, England)), 26(1), 139–140. https://doi.org/10.1093/bioinformatics/btp616
   PubMed Web of Science ®Google Scholar
• Siveke, J. T., Einwachter, H., Sipos, B., Lubeseder-Martellato, C., Kloppel, G., & Schmid, R. M. (2007). Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell, 12(3), 266–279. https://doi.org/10.1016/j.ccr.2007.08.002
   PubMed Web of Science ®Google Scholar
• Sun, D., Wang, X., Sui, G., Chen, S., Yu, M., & Zhang, P. (2018). Downregulation of miR-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins. International Journal of Oncology, 52(5), 1491–1503. https://doi.org/10.3892/ijo.2018.4315
   PubMed Web of Science ®Google Scholar
• Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017). GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 45(W1), W98–W102. https://doi.org/10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Varo, R., Crowley, V. M., Sitoe, A., Madrid, L., Serghides, L., Bila, R., Mucavele, H., Mayor, A., Bassat, Q., & Kain, K. C. (2017). Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria. Malaria Journal, 16(1), 215. https://doi.org/10.1186/s12936-017-1858-0
   PubMed Web of Science ®Google Scholar
• Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., Harris, M., Reni, M., Dowden, S., Laheru, D., Bahary, N., Ramanathan, R. K., Tabernero, J., Hidalgo, M., Goldstein, D., … Renschler, M. F. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 369(18), 1691–1703. https://doi.org/10.1056/NEJMoa1304369
   PubMed Web of Science ®Google Scholar
• Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H. (2011). Pancreatic cancer: Understanding and overcoming chemoresistance. Nature Reviews. Gastroenterology & Hepatology, 8(1), 27–33. https://doi.org/10.1038/nrgastro.2010.188
   PubMed Web of Science ®Google Scholar
• Wang, Z. Q., Zhang, M. Y., Deng, M. L., Weng, N. Q., Wang, H. Y., & Wu, S. X. (2017). Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One, 12(9), e0184969. https://doi.org/10.1371/journal.pone.0184969
   PubMed Web of Science ®Google Scholar
• Youssef, J., & Badr, M. (2011). Peroxisome proliferator-activated receptors and cancer: Challenges and opportunities. British Journal of Pharmacology, 164(1), 68–82. https://doi.org/10.1111/j.1476-5381.2011.01383.x
   PubMed Web of Science ®Google Scholar